Is CNTX or COLL more undervalued in 2026?

CirclFi compares Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical, Inc. (COLL) using 13 institutional-grade valuation models. CNTX has a Quality of Company score of 4.5/10 while COLL scores 9.2/10.

Which is a better buy — CNTX or COLL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CNTX and COLL valuations compare?

CNTX at $2.85 and COLL at $33.61 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CNTX vs COLL Valuation Comparison 2026 — Intrinsic Value Analysis

CNTX

Pharmaceutical Preparations

Context Therapeutics Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$2.85

Last close

Models

7/13

Active

COLL

Pharmaceutical Preparations

Collegium Pharmaceutical, Inc.

Quality

9.2

out of 10

Value Trap

SAFE

Price

$33.61

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CNTX Fair Value	CNTX Upside	COLL Fair Value	COLL Upside
Bayesian DCF	Intrinsic	$0.94	-67.0%	$138.44	+311.9%
Earnings Power Value	Intrinsic	—	—	$30.34	-9.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.10	-95.5%	$27.80	-17.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CNTX vs COLL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CNTX vs COLL — Which Stock Is More Undervalued?

COLL scores higher with a 9.2/10 quality rating vs CNTX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical, Inc. (COLL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CNTX currently trades at $2.85 with a QOC of 4.5/10, while COLL trades at $33.61 with a QOC of 9.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).